In studies over the past three years, researchers at the Perelman School of Medicine at the University of Pennsylvania and the Scheie Eye Institute have shown the safety and efficacy of the new treatment in five groups of patients representing many age groups.
The new research, published online this week in the Archives of Ophthalmology, describes how patients received an injection of genes into the retina of one eye for the type of LCA caused by a mutation in the RPE65 gene.
Related Articles on Retinal Diseases:
Ophthalmologist-CEO Lloyd Hildebrand Shows Clinicians’ Key Role in Innovation
Researchers Find New Genetic Cause for Retinitis Pigmentosa
Study: Patients With Retinal Disease More Likely to Suffer Strokes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
